Supreme Court Stay Sets Stage for Reconsidering Humphrey's Executor
On Monday, the Supreme Court ruled that President Donald Trump may remove Democratic Federal Trade Commission (FTC) commissioner Rebecca Slaughter without cause while her legal challenge to the termination proceeds.
FTC Bureau of Consumer Protection Director on Privacy Rules and AI Regulation
Chris Mufarrige, the director of the FTC's Bureau of Consumer Protection, spoke last week at the National Advertising Division's Annual Conference in Washington, providing further insight into how the FTC is thinking about key issues.
National Advertising Division 2025 Annual Conference: Highlights and Takeaways
This year's National Advertising Division's (NAD) Annual Conference demonstrated that the self-regulatory process remains an active venue for companies interested in challenging competitor advertising claims. Attorneys from Venable's Advertising and Marketing Group represent both advertisers and challengers at all levels of the NAD process, and this year has been particularly busy with NAD challenges. Read on for this year's conference highlights and what to expect from NAD.
The INFORM Act in Action: First Enforcement Signals the Stakes
Earlier this month, the Federal Trade Commission (FTC) and the Department of Justice (DOJ) together announced a settlement with Whaleco, Inc., the operator of Temu, over allegations that the online marketplace violated the INFORM Act. According to the complaint, Temu failed to provide consumers with required information about sellers or reporting tools to help consumers identify and avoid potentially fraudulent or unsafe products. Under the settlement, Temu will pay $2 million in civil penalties and must put measures in place to bring its practices in line with the law.
FTC Commissioner Mark Meador Highlights Consumer Protection Priorities at NAD Conference
FTC Commissioner Mark Meador spoke at the National Advertising Division's Annual Conference this week in Washington and provided some insight into his views on advertising and consumer protection.
Prescription Drug Advertising Under Scrutiny: New FDA and HHS Enforcement Actions
Last week, President Trump signed a presidential memorandum, "Addressing Misleading Direct-To-Consumer Prescription Drug Advertisements." The memorandum invokes the U.S. Food and Drug Administration's (FDA) authority to regulate prescription drug advertising, noting that the agency has historically required manufacturers, packers, or distributors to provide consumers with materially complete information regarding the benefits and risks of the advertised drug.